CoChat

Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity

Open access

Published version of a preprint

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.

Abstract

Histone H3 lysine 9 dimethylation and trimethylation (H3K9me2/3) are prevalent in human genomes, especially in heterochromatin and specific euchromatic genes. Methylation of H3K9 is modulated by enzymes such as SUV39H1, SUV39H2, SETDB1, SETDB2, and EHMT1/2, which influence cancer progression. This study reveals differential expression of these six H3K9 methyltransferases in tumors, with SUV39H1, SUV39H2, and SETDB1 showing significant links to cancer phenotypes. We developed the "H3K9me3 MtSig" (H3K9me3 methyltransferases signature) based on these findings. H3K9me3 MtSig is unique to various tumors, with prognostic significance and associations with key signaling pathways, especially in glioblastoma (GBM). Elevated H3K9me3 MtSig was observed in GBM samples, correlating with the G2/M cell cycle and reduced immune responses. H3K9me3-mediated repetitive sequence silencing by H3K9me3 MtSig contributed to these phenotypes, and inhibiting H3K9me3 MtSig in patient-derived GBM cells suppressed proliferation and increased immune responses. H3K9me3 MtSig serves as an independent prognostic factor and potential therapeutic target.

Overview

CoChat Summary

TL;DR

This multi-omics study defines an H3K9me3 methyltransferases signature (H3K9me3 MtSig) from SUV39H1, SUV39H2, and SETDB1 and links it to poor prognosis, G2/M checkpoint activation, and reduced immune responses, especially in glioblastoma (GBM). In patient-derived GBM cells, H3K9me3 MtSig maintains H3K9me3 at repetitive elements, and its inhibition suppresses proliferation while inducing immune-response genes.

Key findings

  • Across cancers, SUV39H1, SUV39H2, and SETDB1 showed correlated expression and prognostic relevance; high expression was associated with poorer survival in GBM, SARC, LIHC, and BRCA with hazard ratios of 1.5 to 2.2, and SUV39H1/SUV39H2/SETDB1 high expression was associated with poorer prognosis with hazard ratios of 1.3 to 1.8 in GBM and KIRP.
  • H3K9me3 MtSig was positively correlated with the G2/M checkpoint (pan-cancer R = 0.63, P < 0.001; GBM R = 0.81, P < 0.001) and negatively correlated with immune responses (pan-cancer R = -0.16, P < 0.001; GBM R = -0.6, P < 0.001).
  • In GBM cells, knockdown of SUV39H1, SUV39H2, and SETDB1 reduced tumorsphere formation; SUV39H1 knockdown reduced H3K9me3 enrichment at repetitive elements, downregulated G2/M checkpoint genes, upregulated immune-response genes, and caused G2/M arrest.
  • Drug susceptibility screening linked elevated H3K9me3 MtSig to increased sensitivity to compounds including GDC-0879, vemurafenib, MK-0752, BRD-K33199242, and PLX-4720 by CTRP2.0, and EPZ-5676, oxymatrine, ganetespib, rubitecan, dirithromycin, and simvastatin by PRISM.

Methods

  • Integrated multi-omic analyses of TCGA data across 33 cancer types, with paired tumor-normal analyses in 20 cancer types, including expression, survival, SNV, CNV, and DNA methylation; H3K9me3 MtSig was calculated by ssGSEA using SUV39H1, SUV39H2, and SETDB1.
  • Pathway and single-cell analyses used GSEA and the Extended GBmap dataset, comprising 16 datasets from 110 GBM patients and over 330,000 cells.
  • Experimental validation used patient-derived GBM cells (GSC3565 and public GSC23 ChIP-seq), with H3K9me3 ChIP-seq, RNA-seq, qPCR, tumorsphere assays, cell cycle analysis, immunohistochemistry, immunofluorescence, and H3K9M plasmid-mediated H3K9me3 depletion; clinical prediction models used TCGA GBM and CGGA GBM data, and drug susceptibility used CTRP2.0 and PRISM.

Limitations

  • The paper states that further studies are necessary to validate and explore the immunotherapy-response associations in other cancer types, and that the drug-sensitivity findings require additional research and validation.
  • The paper states that future studies should investigate the specific molecular mechanisms connecting H3K9me3 MtSig with drug sensitivity and the detailed mechanisms linking H3K9 methylation, immune response pathways, and the tumor microenvironment.
  • Evident from the text: the experimental validation is largely cell-based in patient-derived GBM cells/GSCs, with no in vivo animal model reported in the Methods; the clinical prediction model is developed and revalidated retrospectively using TCGA and CGGA data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41698-025-00829-5

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Expression patterns and prognostic relevance of H3K9 methyltransferases in pan-cancer. A The expressions of the six H3K9 methyltransferases in pan-cancer, with red indicating upregulation and blue indicating downregulation. B Expression correlations of H3K9 methyltransferases in pan-cancer. C The prognostic value of the H3K9 methyltransferases was analyzed using univariate Cox regression, where red represents a correlation between high expression of H3K9 methyltransferases and poor survival, and blue represents a correlation with better survival. D–F Analysis of SUV39H1 (D), SUV39H2 (E), SETDB1 (F) with the objective response rate (ORR) to anti-PD-1/PD-L1 immunotherapies.
Fig. 1 Expression patterns and prognostic relevance of H3K9 methyltransferases in pan-cancer. A The expressions of the six H3K9 methyltransferases in pan-cancer, with red indicating upregulation and blue indicating downregulation. B Expression correlations of H3K9 methyltransferases in pan-cancer. C The prognostic value of the H3K9 methyltransferases was analyzed using univariate Cox regression, where red represents a correlation between high expression of H3K9 methyltransferases and poor survival, and blue represents a correlation with better survival. D–F Analysis of SUV39H1 (D), SUV39H2 (E), SETDB1 (F) with the objective response rate (ORR) to anti-PD-1/PD-L1 immunotherapies.CC BY-NC-ND · PubMed Central
Fig. 2 Genetic and epigenetic alterations of the H3K9 methyltransferases genes. A Waterfall plot demonstrating the mutation frequency of the H3K9 methyltransferase genes in pan-cancer. B Histogram showing the frequency of CNVs for H3K9 methyltransferase genes in pan-cancer. C Spearman correlation analysis of the transcriptional expression and CNVs of the H3K9 methyltransferase genes. D DNA methylation in the H3K9 methyltransferase genes in pan-cancer. Genes with high and low DNA methylation are marked in red and blue, respectively. E Spearman correlation analysis of DNA methylation and expression of the H3K9 methyltransferase genes.
Fig. 2 Genetic and epigenetic alterations of the H3K9 methyltransferases genes. A Waterfall plot demonstrating the mutation frequency of the H3K9 methyltransferase genes in pan-cancer. B Histogram showing the frequency of CNVs for H3K9 methyltransferase genes in pan-cancer. C Spearman correlation analysis of the transcriptional expression and CNVs of the H3K9 methyltransferase genes. D DNA methylation in the H3K9 methyltransferase genes in pan-cancer. Genes with high and low DNA methylation are marked in red and blue, respectively. E Spearman correlation analysis of DNA methylation and expression of the H3K9 methyltransferase genes.CC BY-NC-ND · PubMed Central
Fig. 3 H3K9me3 MtSig and regulated pathways in pan-cancer. A The differences in H3K9me3 MtSig between tumor and normal tissues are illustrated. B Overall cancer prognosis based on H3K9me3 MtSig score. C, D GSEA on hallmark pathways in high versus low H3K9me3 MtSig tumors in pan-cancer. C Illustrates pathway associated with the G2/M checkpoint, while (D) showcases pathways related to immune responses. NES scores and adjusted P values are included on the figure panel. E, F H3K9me3 MtSig is associated with G2/M checkpoint (E) and immune responses (F) in various cancer types.
Fig. 3 H3K9me3 MtSig and regulated pathways in pan-cancer. A The differences in H3K9me3 MtSig between tumor and normal tissues are illustrated. B Overall cancer prognosis based on H3K9me3 MtSig score. C, D GSEA on hallmark pathways in high versus low H3K9me3 MtSig tumors in pan-cancer. C Illustrates pathway associated with the G2/M checkpoint, while (D) showcases pathways related to immune responses. NES scores and adjusted P values are included on the figure panel. E, F H3K9me3 MtSig is associated with G2/M checkpoint (E) and immune responses (F) in various cancer types.CC BY-NC-ND · PubMed Central
Fig. 4 Expression and prognostic relevance of H3K9me3 MtSig in GBM. A Differential expressions of SUV39H1, SUV39H2, SETDB1, and H3K9me3 in GBM and non-neoplastic tissues, with representative images (left) and quantification of percent positivity (right). Experiments were performed in triplicate (n = 3) and statistical significance was determined using Student’s t-test. B Forest plot depicting the association between the H3K9me3 MtSig and survival outcomes (OS, DSS) in GBM patients across multiple cohorts. Each row represents a different GBM dataset, with horizontal lines indicating the hazard ratio and 95% confidence interval. A hazard ratio exceeding 1 suggests that higher H3K9me3 MtSig scores correlate with poorer survival outcomes. *P < 0.05, **P < 0.01, ***P < 0.001.
Fig. 4 Expression and prognostic relevance of H3K9me3 MtSig in GBM. A Differential expressions of SUV39H1, SUV39H2, SETDB1, and H3K9me3 in GBM and non-neoplastic tissues, with representative images (left) and quantification of percent positivity (right). Experiments were performed in triplicate (n = 3) and statistical significance was determined using Student’s t-test. B Forest plot depicting the association between the H3K9me3 MtSig and survival outcomes (OS, DSS) in GBM patients across multiple cohorts. Each row represents a different GBM dataset, with horizontal lines indicating the hazard ratio and 95% confidence interval. A hazard ratio exceeding 1 suggests that higher H3K9me3 MtSig scores correlate with poorer survival outcomes. *P < 0.05, **P < 0.01, ***P < 0.001.CC BY-NC-ND · PubMed Central
Fig. 5 H3K9me3 MtSig regulates G2/M checkpoint and immune responses through H3K9me3-mediated repeat elements silencing in GBM. A–C UMAP visualization of G2/M checkpoint (A), H3K9me3 MtSig (B), and immune responses (C) in cancer cells from GBM tissues by single-cell analysis. D Quantification of H3K9me3 signal enrichment in functional genomic elements, including Repeats, Heterochromatin, Promoters, Enhancers, CpG Islands, and Repressed. E Repeat elements annotation of H3K9me3 chromatin binding peaks in GSC3565 cells. F, G Genomic tracks displaying the H3K9me3 ChIP-seq peaks and repeat elements across the entire genome (F), along with a representative repeat elements—AluSx region (G) in GSC3565 and GSC23 cells. H Quantification of tumorsphere numbers in GSC3565 cells after MtSig (SUV39H1, SUV39H2, and SETDB1) knockdown. I qPCR analysis showing the knockdown efficiency for SUV39H1, SUV39H2, and SETDB1 in GSC3565 cells. J Quantification of differential H3K9me3 peaks after SUV39H1 knockdown in functional genomic elements. K Annotation of differential H3K9me3 chromatin binding peaks after SUV39H1 knockdown, focusing on repeat elements. L Volcano plot showing differentially expressed genes after SUV39H1 knockdown in GSC3565 cells. M, N GSEA plots showing enrichment of G2/M checkpoint (M) and immune response pathways (N) after SUV39H1 knockdown. O qPCR detection of indicated genes including G2/M checkpoint-related genes in control vs. SUV39H1 knockdown GSC3565 cells. P Cell cycle analysis showing the distribution of G1, S, and G2/M phases in indicated GSCs. *P < 0.05, **P < 0.01, ***P < 0.001.
Fig. 5 H3K9me3 MtSig regulates G2/M checkpoint and immune responses through H3K9me3-mediated repeat elements silencing in GBM. A–C UMAP visualization of G2/M checkpoint (A), H3K9me3 MtSig (B), and immune responses (C) in cancer cells from GBM tissues by single-cell analysis. D Quantification of H3K9me3 signal enrichment in functional genomic elements, including Repeats, Heterochromatin, Promoters, Enhancers, CpG Islands, and Repressed. E Repeat elements annotation of H3K9me3 chromatin binding peaks in GSC3565 cells. F, G Genomic tracks displaying the H3K9me3 ChIP-seq peaks and repeat elements across the entire genome (F), along with a representative repeat elements—AluSx region (G) in GSC3565 and GSC23 cells. H Quantification of tumorsphere numbers in GSC3565 cells after MtSig (SUV39H1, SUV39H2, and SETDB1) knockdown. I qPCR analysis showing the knockdown efficiency for SUV39H1, SUV39H2, and SETDB1 in GSC3565 cells. J Quantification of differential H3K9me3 peaks after SUV39H1 knockdown in functional genomic elements. K Annotation of differential H3K9me3 chromatin binding peaks after SUV39H1 knockdown, focusing on repeat elements. L Volcano plot showing differentially expressed genes after SUV39H1 knockdown in GSC3565 cells. M, N GSEA plots showing enrichment of G2/M checkpoint (M) and immune response pathways (N) after SUV39H1 knockdown. O qPCR detection of indicated genes including G2/M checkpoint-related genes in control vs. SUV39H1 knockdown GSC3565 cells. P Cell cycle analysis showing the distribution of G1, S, and G2/M phases in indicated GSCs. *P < 0.05, **P < 0.01, ***P < 0.001.CC BY-NC-ND · PubMed Central
Fig. 6 Impact of H3K9me3 modification on GBM cell proliferation, gene expression, and tumorigenesis. A Immunofluorescence images (left panel) showing GFP signal, H3K9me3 staining, and merged images in GBM cells expressing GFP-H3.3 and GFP-H3K9M plasmids. The right panel quantifies the percentage of H3K9me3-positive cells. B GFP-H3K9M expression decreases GSC3565 cell proliferation, with representative images (left) and quantification (right). C qPCR analysis of mcBOX, CDK16, and IFNA1 expression in GSC3565 cells following indicated transfection. For (J) and (K), data are presented as mean ± SEM (n = 3). Statistical analysis was performed using Student’s t-test. D The working model showing the signal cascade between H3K9me3 MtSig, H3K9me3, repeat elements, cell cycle regulation (G2/M checkpoint), and immune responses in the context of GBM. Created with BioRender.com. **P < 0.01, ***P < 0.001.
Fig. 6 Impact of H3K9me3 modification on GBM cell proliferation, gene expression, and tumorigenesis. A Immunofluorescence images (left panel) showing GFP signal, H3K9me3 staining, and merged images in GBM cells expressing GFP-H3.3 and GFP-H3K9M plasmids. The right panel quantifies the percentage of H3K9me3-positive cells. B GFP-H3K9M expression decreases GSC3565 cell proliferation, with representative images (left) and quantification (right). C qPCR analysis of mcBOX, CDK16, and IFNA1 expression in GSC3565 cells following indicated transfection. For (J) and (K), data are presented as mean ± SEM (n = 3). Statistical analysis was performed using Student’s t-test. D The working model showing the signal cascade between H3K9me3 MtSig, H3K9me3, repeat elements, cell cycle regulation (G2/M checkpoint), and immune responses in the context of GBM. Created with BioRender.com. **P < 0.01, ***P < 0.001.CC BY-NC-ND · PubMed Central
Fig. 7 Clinical prediction model incorporating H3K9me3 MtSig using TCGA GBM dataset. A Nomogram predicting mortality rate of patients based on clinical-pathological factors and prognostic H3K9me3 MtSig. B Risk survival status plot of H3K9me3 MtSig. C Kaplan-Meier survival curve stratified by H3K9me3 MtSig, showing the difference in overall survival between high and low H3K9me3 MtSig groups. Log-rank test P value is provided. D Calibration of the nomogram for predicting 1-year, 2-year, and 3-year outcomes, showing the consistency between predicted and observed results. The position relative to the 45-degree line indicates the performance of the nomogram, where the 45-degree line represents the ideal prediction. E Concordance index showing measure of concordance of predictor with survival of patients.
Fig. 7 Clinical prediction model incorporating H3K9me3 MtSig using TCGA GBM dataset. A Nomogram predicting mortality rate of patients based on clinical-pathological factors and prognostic H3K9me3 MtSig. B Risk survival status plot of H3K9me3 MtSig. C Kaplan-Meier survival curve stratified by H3K9me3 MtSig, showing the difference in overall survival between high and low H3K9me3 MtSig groups. Log-rank test P value is provided. D Calibration of the nomogram for predicting 1-year, 2-year, and 3-year outcomes, showing the consistency between predicted and observed results. The position relative to the 45-degree line indicates the performance of the nomogram, where the 45-degree line represents the ideal prediction. E Concordance index showing measure of concordance of predictor with survival of patients.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

14 Valid · 2 Not valid · 6 Not checked · 69 Own results and interpretations

44 more claims

Create a free account to see all 91 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 21
  • It may state two separate claims as one. 30
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 53 references

Cited by

See all 10

Metadata

Authors
Xie, Q., Du, Y., Ghosh, S., Rajendran, S., Cohen-Gadol, A. A., Baizabal, J.-M., Nephew, K. P., Han, L., & Shen, J.
Affiliations
  • Indiana University School of Medicine (US)
  • Indiana University Bloomington (US)
  • Indiana University Health (US)
  • Indiana University Indianapolis (US)
Corresponding author
  • Han, Leng
  • Shen, Jia
Venue
NPJ Precision Oncology
Published
2025-03-20
Volume
9
Issue
1
Pages
78-78
ISSN
2397-768X (ISSN-L)
OpenAlex
W4408666086
Cited by
10
References
49
Citations by year
2026: 4 · 2025: 6
FWCI
6.46
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Precision Oncology (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
Funders
  • U.S. Department of Health & Human Services | National Institutes of Health (R01HG011633, R01CA262623)
  • This study received funding from the Indiana University School of Medicine Start-Up Fund (to J. Shen) and the Schwarz Family and Friends Cancer Research Fund (to J. Shen).
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
Keywords
glioblastoma, H3K9me3, histone methyltransferase, SUV39H1, SUV39H2, SETDB1, SETDB2, prognostic factors, antitumor immunity, G2/M phase, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity. https://app.cochat.ai/papers/10.1038/s41698-025-00829-5
The paper
Xie, Q., Du, Y., Ghosh, S., Rajendran, S., Cohen-Gadol, A. A., Baizabal, J.-M., Nephew, K. P., Han, L., & Shen, J. (2025). Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity. NPJ Precision Oncology. https://doi.org/10.1038/s41698-025-00829-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.